切换至 "中华医学电子期刊资源库"

中华介入放射学电子杂志 ›› 2018, Vol. 06 ›› Issue (02) : 127 -132. doi: 10.3877/cma.j.issn.2095-5782.2018.02.008

所属专题: 文献

专题研究·肿瘤介入

经导管肝动脉化疗栓塞术的技术细节与进展
李智1, 倪才方1,()   
  1. 1. 215006 苏州大学附属第一医院介入科
  • 收稿日期:2017-12-26 出版日期:2018-05-01
  • 通信作者: 倪才方
  • 基金资助:
    国家自然科学基金青年科学基金项目(81501563); 江苏省青年医学人才项目(QNRC2016711); 苏州科技局民生科技项目(SYS201611)

Technical details and progress of transcatheter hepatic arterial chemoembolization

Zhi Li1, Caifang Ni1,()   

  1. 1. Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China
  • Received:2017-12-26 Published:2018-05-01
  • Corresponding author: Caifang Ni
  • About author:
    Corresponding author: Ni Caifang, Email:
引用本文:

李智, 倪才方. 经导管肝动脉化疗栓塞术的技术细节与进展[J/OL]. 中华介入放射学电子杂志, 2018, 06(02): 127-132.

Zhi Li, Caifang Ni. Technical details and progress of transcatheter hepatic arterial chemoembolization[J/OL]. Chinese Journal of Interventional Radiology(Electronic Edition), 2018, 06(02): 127-132.

经导管肝动脉化疗栓塞术(TACE)是治疗肝癌的最常用方法,但其技术细节存在较多争议,难以标准化。通过文献复习,笔者发现:超选择插管是TACE的基本要求;碘油以其可塑的栓塞作用成为不可或缺的栓塞材料;追加固体栓塞材料可延长生存期;化疗药物的作用值得质疑;"按需TACE"与"TACE抵抗"的理念逐渐被接受。本文就此进行了综述。

Transcatheter hepatic arterial chemoembolization (TACE) is the most commonly used method in the treatment of hepatocellular carcinoma, but its technical details are controversial and difficult to standardize. Through literature review, we found that superselective catheterization was the basic requirement of TACE; Lipiodol has become an indispensable embolic material for its plastic embolization; Adding solid embolization materials could prolong the survival time; The role of chemotherapeutic drugs is questionable; And the concepts of "on-demand TACE" and "TACE resistance" are gradually accepted.

[1]
Yamada R, Sato M, Kawabata M, et al. Hepatic artery embolization in 120 patients with unresectable hepatoma[J]. Radiology, 1983, 148(2): 397-401.
[2]
Matsui O, Kadoya M, Yoshikawa J, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization[J]. Radiology, 1993, 188(1): 79-83.
[3]
Horikawa M, Miyayama S, Irie T, et al. Development of conventional transarterial chemoembolization for hepatocellular carcinomas in Japan: historical, strategic, and technical review[J]. AJR Am J Roentgenol, 2015, 205(4): 764-773.
[4]
Miyayama S, Matsui O, Taki K, et al. Extrahepatic blood supply to hepatocellular carcinoma: angiographic demonstration and transcatheter arterial chemoembolization[J]. Cardiovasc Intervent Radiol, 2006, 29(1): 39-48.
[5]
Miyayama S, Yamashiro M, Okuda M, et al. Anastomosis between the hepatic artery and the extrahepatic collateral or between extrahepatic collaterals: observation on angiography[J]. J Med Imaging Radiat Oncol, 2009, 53(3): 271-282.
[6]
Miyayama S, Matsui O. Superselective conventional transarterial chemoembolization for hepatocellular carcinoma: rationale, technique, and outcome[J]. J Vasc Interv Radiol, 2016, 27(9): 1269-1278.
[7]
Golfieri R, Renzulli M, Mosconi C, et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? [J]. J Vasc Interv Radiol, 2013, 24(4): 509-517.
[8]
Yamakado K, Miyayama S, Hirota S, et al. Hepatic arterial embolization for unresectable hepatocellular carcinomas: do technical factors affect prognosis? [J]. Jpn J Radiol, 2012, 30(7): 560-566.
[9]
李照,朱继业.《原发性肝癌诊疗规范(2017年版)》解读[J].临床肝胆病杂志,2017,33(9): 1655-1657.
[10]
Idee JM, Guiu B. Use of lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review[J]. Crit Rev Oncol Hematol, 2013, 88(3): 530-549.
[11]
Konno T. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium[J]. Cancer, 1990, 66(9): 1897-1903.
[12]
Kan Z, Madoff DC. Liver anatomy: microcirculation of the liver[J]. Semin Intervent Radiol, 2008, 25(2): 77-85.
[13]
Kan Z. Dynamic study of iodized oil in the liver and blood supply to hepatic tumors. An experimental investigation in several animal species[J]. Acta Radiol Suppl, 1996, 408: 1-25.
[14]
Goseki N, Nosaka T, Endo M, et al. Nourishment of hepatocellular carcinoma cells through the portal blood flow with and without transcatheter arterial embolization[J]. Cancer, 1995, 76(5): 736-742.
[15]
Miyayama S, Matsui O, Yamashiro M, et al. Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between local tumor recurrence and visualization of the portal vein with iodized oil[J]. J Vasc Interv Radiol, 2007, 18(3): 365-376.
[16]
Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma[J]. Br J Cancer, 2014, 111(2): 255-264.
[17]
Li Z, Ni RF, Busireddy KK, et al. Cerebral lipiodol embolism following transcatheter arterial chemoembolization for hepatocellular carcinoma: a report of two cases and literature review[J]. Chin Med J(Engl), 2011, 124(24): 4355-4358.
[18]
Nakao N, Uchida H, Kamino K, et al. Determination of the optimum dose level of lipiodol in transcatheter arterial embolization of primary hepatocellular carcinoma based on retrospective multivariate analysis[J]. Cardiovasc Intervent Radiol, 1994, 17(2): 76-80.
[19]
Tam KY, Leung KC, Wang YX. Chemoembolization agents for cancer treatment[J]. Eur J Pharm Sci, 2011, 44(1-2): 1-10.
[20]
de Baere T, Dufaux J, Roche A, et al. Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and doxorubicin: experimental study[J]. Radiology, 1995, 194(1): 165-170.
[21]
Park C, Choi SI, Kim H, et al. Distribution of Lipiodol in hepatocellular carcinoma[J]. Liver, 1990, 10(2): 72-78.
[22]
Bhattacharya S, Dhillon AP, Winslet MC, et al. Human liver cancer cells and endothelial cells incorporate iodised oil[J]. Br J Cancer, 1996, 73(7): 877-881.
[23]
Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2012, 88(3): 53-71.
[24]
Kim DY, Ryu HJ, Choi JY, et al. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma[J]. Aliment Pharmacol Ther 2012, 35(11): 1343-1350.
[25]
Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies[J]. Cardiovasc Intervent Radiol, 2007, 30(1): 6-25.
[26]
Geschwind JF, Ramsey DE, Cleffken B, et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency[J]. Cardiovasc Intervent Radiol, 2003, 26(2): 111-117.
[27]
Takayasu K, Arii S, Ikai I, et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis[J]. AJR Am J Roentgenol, 2010, 194(3): 830-837.
[28]
Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma[J]. Semin Intervent Radiol, 2013, 30(1): 3-11.
[29]
Jin B, Wang D, Lewandowski RJ, et al. Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma[J]. AJR Am J Roentgenol, 2011, 196(4): 919-928.
[30]
施昌盛,杨庆,李成. Embosphere微球联合弹簧圈栓塞治疗大咯血的疗效分析[J/CD].中华介入放射学电子杂志, 2017, 5(4):269-272.
[31]
Brown DB, Pilgram TK, Darcy MD, et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents[J]. J Vasc Interv Radiol, 2005, 16(12): 1661-1666.
[32]
Illum L, Davis SS. The targeting of drugs parenterally by use of microspheres[J]. J Parenter Sci Technol, 1982, 36(6): 242-248.
[33]
Bastian P, Bartkowski R, Kohler H, et al. Chemo-embolization of experimental liver metastases. Part I: distribution of biodegradable microspheres of different sizes in an animal model for the locoregional therapy[J]. Eur J Pharm Biopharm, 1998, 46(3): 243-254.
[34]
Lu W, Li Y, He X, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors[J]. Hepatogastroenterology, 2003, 50(54): 2079-2083.
[35]
Kan Z, Wright K, Wallace S. Ethiodized oil emulsions in hepatic microcirculation: in vivo microscopy in animal models[J]. Acad Radiol, 1997, 4(4): 275-282.
[36]
El-Serag HB. Hepatocellular carcinoma[J]. N Engl J Med, 2011, 365(12): 1118-1127.
[37]
Tsochatzis EA, Fatourou E, O'Beirne J, et al. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(12): 3069-3077.
[38]
Kawai S, Okamura J, Ogawa M, et al. Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma—a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin(first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan[J]. Cancer Chemother Pharmacol, 1992, 31(Suppl): S1-S6.
[39]
Chang JM, Tzeng WS, Pan HB, et al. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study[J]. Cancer, 1994, 74(9): 2449-2453.
[40]
Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J]. Lancet, 2002, 359(9319): 1734-1739.
[41]
Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2010, 33(3): 541-551.
[42]
Meyer T, Kirkwood A, Roughton M, et al. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs. embolisation alone for hepatocellular carcinoma[J]. Br J Cancer, 2013, 108(6): 1252-1259.
[43]
Tak E, Lee S, Lee J, et al. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells[J]. J Hepatol, 2011, 54(2): 328-339.
[44]
Facciorusso A, Licinio R, Muscatiello N, et al. Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients[J]. World J Hepatol, 2015, 7(16): 2009-2019.
[45]
Ernst O, Sergent G, Mizrahi D, et al. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response[J]. AJR Am J Roentgenol, 1999, 172(1): 59-64.
[46]
Yamashita Y, Torashima M, Oguni T, et al. Liver parenchymal changes after transcatheter arterial embolization therapy for hepatoma: CT evaluation[J]. Abdom Imaging, 1993, 18(4): 352-356.
[47]
Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update[J]. Oncology, 2014, 87(Suppl 1): 22-31.
[48]
Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology(JSH)2010 updated version[J]. Dig Dis, 2011, 29(3): 339-364.
[49]
Sieghart W, Hucke F, Pinter M, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma[J]. Hepatology, 2013, 57(6): 2261-2273.
[50]
Adhoute X, Penaranda G, Naude S, et al. Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process[J]. J Hepatol, 2015, 62(4): 855-862.
[51]
Chen L, Ni CF, Chen SX, et al. A modified model for assessment for retreatment with transarterial chemoembolization in Chinese hepatocellular carcinoma patients[J]. J Vasc Interv Radiol, 2016, 27(9): 1288-1297.
[1] 唐梅, 周丽, 牛岑月, 周小童, 王倩. ICG荧光导航的腹腔镜肝切除术临床意义[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 655-658.
[2] 曾繁利, 齐秩凯, 杨贺庆. 两种经Glisson蒂鞘解剖路径肝切除术治疗原发性肝癌的肿瘤学疗效及风险比对[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 525-527.
[3] 林巧, 周丽. RFA联合LAH术治疗原发性肝癌并门静脉癌栓的临床效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 521-524.
[4] 马立伟, 贾志强, 陈午盛, 邵明亮, 刘琼, 段玉松. CalliSpheres载药微球联合碘化油治疗肝癌的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(04): 369-372.
[5] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[6] 董奕琦, 罗耀兵, 刘涛, 张岚, 杨明. 血流拓扑学肝分段与Couinaud肝分段在原发性肝癌术前评估及手术规划中的应用价值[J/OL]. 中华普外科手术学杂志(电子版), 2022, 16(04): 423-426.
[7] 吴警, 吐尔洪江·吐逊, 温浩. 肝切除术前肝功能评估新进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 889-893.
[8] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[9] 韩冰, 顾劲扬. 深度学习神经网络在肝癌诊疗中的研究及应用前景[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 480-485.
[10] 赫嵘, 贾哲, 张珂, 李代京, 张萌, 蒋力. 基于PSM分析腹腔镜肝切除联合Hassab术治疗合并门静脉高压症肝癌疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 376-383.
[11] 葛云鹏, 崔红元, 宋京海. 人工智能在原发性肝癌诊断、治疗及预后中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 367-371.
[12] 鲍乐, 刘颖, 王友彬, 陈龙, 朱玉芝, 梁爽, 权鹤太, 李鹏飞. 还阳通络灸在原发性肝癌介入治疗中的临床应用研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(03): 197-202.
[13] 广东省护士协会介入护士分会, 广东省医师协会介入医师分会. 原发性肝癌低血糖患者护理规范管理专家共识[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 709-714.
[14] 肖西洋, 金光, 孙润杰, 崔鹤松. IL-10基因位点rs1554286(G/A)多态性与延边地区原发性肝癌的预后分析[J/OL]. 中华临床医师杂志(电子版), 2023, 17(11): 1169-1175.
[15] 黄学卿, 魏楠, 蒋天鹏, 安天志, 王黎洲, 许敏, 周石. 超声引导经远端桡动脉入路行肝癌TACE术的临床研究[J/OL]. 中华介入放射学电子杂志, 2023, 11(03): 251-256.
阅读次数
全文


摘要